INCYTE CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 52.56 USD | +1.70% |
|
+1.23% | -16.29% |
| Apr. 24 | Oppenheimer Adjusts Incyte Price Target to $84 From $92, Maintains Outperform Rating | MT |
| Apr. 23 | Transcript : Escient Pharmaceuticals, Inc., Incyte Corporation - M&A Call |
Presenter SpeechPablo Cagnoni (Executives)Good afternoon, everyone. Welcome to those here in p...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Incyte Corporation specializes in the research & development of therapeutic products mainly intended for the treatment of cancers and inflammatory disorders. Net sales break down by revenue source as follows:
- product sales (85.6%);
- royalties (14.2%);
- income from research and cooperation agreements (0.2%).
Sector
Pharmaceuticals
Calendar
2024-04-30
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
51.68
USD
Average target price
75.2
USD
Spread / Average Target
+45.51%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -16.29% | 11.6B | |
| -4.06% | 86.13B | |
| +1.97% | 39.82B | |
| +56.59% | 25.23B | |
| -14.82% | 15.36B | |
| -8.82% | 11.95B | |
| -41.58% | 11.51B | |
| +6.14% | 8.71B | |
| -7.02% | 8.12B | |
| +0.95% | 7.72B |
- Stock Market
- Equities
- INCY Stock
- News Incyte Corporation
- Transcript : Incyte Corporation - Shareholder/Analyst Call
